Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. - Wikidata - awgldk - TriplyDB

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

http://www.wikidata.org/entity/Q36324236

about

LRP-1: a checkpoint for the extracellular matrix proteolysis Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion Transient reduction of placental angiogenesis in PAI-1-deficient mice Shear stress-induced Ets-1 modulates protease inhibitor expression in microvascular endothelial cells Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice.Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells.Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.The plasminogen system in microdissected colonic mucosa distant from an isolated adenoma.Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.Pleiotropic functions of plasminogen activator inhibitor-1.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions Degradation of internalized αvβ5 integrin is controlled by uPAR bound uPA: effect on β1 integrin activity and α-SMA stress fiber assembly.Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability.Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.SERPINE1 (PAI-1) is a prominent member of the early G0 --> G1 transition "wound repair" transcriptome in p53 mutant human keratinocytes.Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.SERPINE1 (PAI-1) is deposited into keratinocyte migration "trails" and required for optimal monolayer wound repair Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.Provisional Matrix Deposition in Hemostasis and Venous Insufficiency: Tissue Preconditioning for Nonhealing Venous Ulcers.Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.Old dogs and new tricks: proteases, inhibitors, and cell migration.Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.Revisiting the matricellular concept.Membrane associated proteases and their inhibitors in tumour angiogenesis.MT1-MMP regulates the turnover and endocytosis of extracellular matrix fibronectin Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance.Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.Plasminogen Activator Inhibitor-1 Controls Vascular Integrity by Regulating VE-Cadherin Trafficking

P2860

Q21285122-486601B9-D961-42A4-9987-1A824A1D2E7D Q24316639-D0F3B2BA-0C9A-4896-BD58-AA91D7FFEAAF Q24317592-A42BD23E-18D4-48FC-99F0-3BD91BE030EE Q24546040-F28C08A0-71B4-4B35-9DEA-3CB0CCCF8F05 Q27308674-279A570F-FE8E-4F5F-BCF8-32AFB0404E94 Q28118812-A7944937-2A38-4A0F-BA12-C60054EF5951 Q28510418-B4ECE88D-80CB-4D34-A7CC-0F147FF815C9 Q28565567-5CB74FE2-37F0-4B5E-B10A-BB08ACC36D42 Q28580473-AA9F0117-4651-4031-9F12-A302EE873884 Q30301012-EC3B5363-0994-4D24-B0FA-40752B3A4148 Q30442725-367EB462-28C8-4C63-873E-5B1072282C68 Q30499283-CF7EF368-0FCA-43AB-B257-3CE9B164D2CB Q33199829-CA2CB90B-2AED-4116-8927-07CB0434C2CA Q33295022-010CE8DC-815E-4B64-9C9F-21804100F53E Q33585332-350777A8-F699-4278-A8F6-6A4A9AE34328 Q33715393-D67B2231-1AB4-4DBC-AEEB-F5CA7D61532E Q33812093-8D5BA282-307E-4774-BFED-F5D4E3DD7D5B Q33984228-9D42D01E-4913-4C0D-B922-A2A6879A4816 Q34217461-DCE560A7-A9D2-44A2-9733-11FD74557A3F Q34217585-5490714B-405D-411F-A820-8C71009997F5 Q34393297-6290A0B8-9B6E-4926-8E81-9661213A66F1 Q34443186-114FCE0E-6BC3-476B-8A4C-AD7FCBBA47C0 Q34567465-EC7851EE-E190-4536-9C3F-4CB7ACB47A3D Q34691253-441457E1-6E21-4B3D-9EDA-F6FF67B71E99 Q34725029-5E7FD6BD-16CE-4A5C-B9ED-64CF02B04E6A Q34735474-10DE815B-29C5-49E7-87C9-EF3127284A40 Q34767246-E70AD5DF-679D-4785-BDBB-99509E723331 Q34887726-C33920C0-9CBE-46A4-BC32-318046915185 Q35156659-7A853C46-77B1-4401-B069-618BDF580D34 Q35159993-3A6DFC0B-0163-40E5-BB52-8BD66D53078D Q35167706-81EC59F9-7D57-4E6D-9C58-AFAC2C15B095 Q35178613-B8AF8331-F758-46CA-8FD1-C80623DC0F2F Q35198048-508334A1-21A9-4CF6-B938-87D500704268 Q35219000-89EDBBA9-8451-4146-951E-FABBDAF40281 Q35233858-04B38E2E-06FC-4141-8CB8-7FC3F48FBC7E Q35587684-92466546-5EE7-45E8-ADDB-DFF7A705D26D Q35630660-2C0273D0-6FBC-4577-A0B0-04BFDDBA4973 Q35688843-AC3034E0-2877-4474-9AF8-F0405F7F7291 Q35757741-6095B2B4-01FD-43D5-8EEA-25AAC5F974C0 Q35880793-4BC32826-10AB-4A4F-921A-C5E23A703119

P2860

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

http://www.wikidata.org/entity/Q36324236

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Plasminogen activator inhibito ...... ces by inactivating integrins.

@ast

Plasminogen activator inhibito ...... ces by inactivating integrins.

@en

type

label

Plasminogen activator inhibito ...... ces by inactivating integrins.

@ast

Plasminogen activator inhibito ...... ces by inactivating integrins.

@en

prefLabel

Plasminogen activator inhibito ...... ces by inactivating integrins.

@ast

Plasminogen activator inhibito ...... ces by inactivating integrins.

@en

P1433

Q36324236-34428EDC-ADD3-4294-BAD6-C72419DC8E99

P1476

Q36324236-1F4F8DF2-8F83-43FC-AED9-33FF99405633

P2093

Q36324236-4362C30C-00A9-47A0-A011-8FBE005BBE6A

Q36324236-671FD40E-BCB5-4854-A84E-E404A05CFFE9

Q36324236-9F80DEA1-700F-4C1B-872D-D05AB2DEB0DF

Q36324236-CD3614BB-37DD-4F27-AAEC-9CB9DFFA558E

P2860

Q36324236-0AA42A79-1D6C-4838-9B8D-2674FA8AAF7B

Q36324236-0B1BF2AB-AC08-4D73-93E5-7BD473757828

Q36324236-0DFEEF71-E257-490C-BF9E-B621306516B3

Q36324236-228C9323-2BC5-4054-AA5E-FA15F421AE15

Q36324236-2A295846-62E0-4830-B307-10CEA7984F9B

Q36324236-2C822C44-5858-4FFE-AC54-F911CF2BDD41

Q36324236-36D70001-5DB4-4DC8-89D2-16CD847B0BBE

Q36324236-37D5E65E-27CF-49B6-A235-E186AEF70083

Q36324236-4A51558E-8247-4C89-9181-5349F6E3AE69

Q36324236-6087F16D-A056-43F7-8367-665E74D4C15C

P304

Q36324236-B05B0624-2849-42BC-914F-773BF1AFBA24

P31

Q36324236-5E733073-2592-4F1B-89A2-97B945F09078

P356

Q36324236-CDB5D110-BCAB-4522-AB43-A7692C0EDCCF

P407

Q36324236-5C02A24C-0078-4334-B4FC-61252E286AA1

P433

Q36324236-C17C60CF-ED2F-4BB5-B616-581A4F3ACBD8

P478

Q36324236-E337184F-C88C-4442-AF14-AF347BB344B1

P577

Q36324236-29E1C4BD-B041-4AB3-B794-1EF9593E708F

P5875

Q36324236-45B2D6E1-1FE1-4E57-80AF-D738034743FC

P698

Q36324236-C3D66D47-9253-4593-BB6D-F5693F640C39

P932

Q36324236-817AB30A-1F90-4543-9C26-30A7008C3994

P356

P1433

Journal of Cell Biology

P1476

Plasminogen activator inhibito ...... ces by inactivating integrins.

@en

P2093

David J Loskutoff

http://www.w3.org/2001/XMLSchema#string

Kathleen Aertgeerts

http://www.w3.org/2001/XMLSchema#string

Ralf-Peter Czekay

http://www.w3.org/2001/XMLSchema#string

Scott A Curriden

http://www.w3.org/2001/XMLSchema#string

P2860

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes

Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity

Cell migration: a physically integrated molecular process

The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility

39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor

The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?

Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor

Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.

Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.

P304

781-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1083/JCB.200208117

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

160

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10874601

http://www.w3.org/2001/XMLSchema#string

P698

12615913

http://www.w3.org/2001/XMLSchema#string

P932

2173358

http://www.w3.org/2001/XMLSchema#string